Insoluble α-synuclein in alzheimer’s disease without lewy body formation

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Neurotoxicity research

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/BF03033777
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Interaction of the Molecular Chaperone αB-Crystallin with α-Synuclein: Effects on Amyloid Fibril Formation and Chaperone Activity

  2004cited by this paper
• Clearance of α-Synuclein Oligomeric Intermediates via the Lysosomal Degradation Pathway

  2004cited by this paper
• The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease.

  2003cited by this paper
• Membrane-bound α-Synuclein Has a High Aggregation Propensity and the Ability to Seed the Aggregation of the Cytosolic Form*

  2002cited by this paper
• Accelerated α‐synuclein fibrillation in crowded milieu

  2002cited by this paper
• Biophysical Properties of the Synucleins and Their Propensities to Fibrillate

  2002cited by this paper
• A Novel Action of Alzheimer's Amyloid β-Protein (Aβ): Oligomeric Aβ Promotes Lipid Release

  2001cited by this paper
• β-amyloid deposits in transgenic mice expressing human β-amyloid precursor protein have the same characteristics as those in Alzheimer's disease

  2001influential reference
• Alpha-synuclein and neurodegenerative diseases

  2001cited by this paper
• Cholesterol Accumulates in Senile Plaques of Alzheimer Disease Patients and in Transgenic APPsw Mice

  2001cited by this paper
• Neurofilament proteins NF-L, NF-M and NF-H in brain of patients with Down syndrome and Alzheimer's disease

  2001influential reference
• Exposure to Long Chain Polyunsaturated Fatty Acids Triggers Rapid Multimerization of Synucleins*

  2001cited by this paper
• A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease.

  2001cited by this paper
• α-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins

  2001cited by this paper
• Lysosomal Membrane Damage in Soluble Aβ-Mediated Cell Death in Alzheimer's Disease

  2001cited by this paper
• β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease

  2001cited by this paper
• Cholesterol, a modulator of membrane-associated Abeta-fibrillogenesis and neurotoxicity.

  2001cited by this paper
• Alzheimer's disease: genes, proteins, and therapy.

  2001cited by this paper
• Accumulation of Insoluble a-Synuclein in Dementia with Lewy Bodies

  2000influential reference
• Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins.

  2000cited by this paper
• a-Synuclein-positive structures in cases with sporadic Alzheimer ’ s disease : morphology and its relationship to tau aggregation

  2000cited by this paper
• α‐Synuclein Inclusions in Alzheimer and Lewy Body Diseases

  2000influential reference
• NACP/α-synuclein and tau constitute two distinctive subsets of filaments in the same neuronal inclusions in brains from a family of parkinsonism and dementia with Lewy bodies: double-immunolabeling fluorescence and electron microscopic studies

  2000cited by this paper
• Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease.

  2000influential reference
• C-terminal α-synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders

  2000influential reference
• Occurrence of human α-synuclein immunoreactive neurons with neurofibrillary tangle formation in the limbic areas of patients with Alzheimer’s disease

  2000cited by this paper
• Lewy body variant of Alzheimer's disease: α‐synuclein in dystrophic neurites of Aβ plaques

  2000cited by this paper
• α-Synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease β-amyloid plaque cores

  1999cited by this paper
• Non-Aβ Component of Alzheimer's Disease Amyloid (NAC) Revisited: NAC and α-Synuclein Are Not Associated with Aβ Amyloid

  1999influential reference
• Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders.

  1998influential reference
• Self‐oligomerization of NACP, the precursor protein of the non‐amyloid β/A4 protein (Aβ) component of Alzheimer's disease amyloid, observed in the presence of a C‐terminal Aβ fragment (residues 25–35)

  1998cited by this paper
• Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes.

  1998cited by this paper
• Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.

  1998cited by this paper
• Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Aβ1‐42 pathogenesis

  1998cited by this paper
• Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease.

  1997cited by this paper
• Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease.

  1997cited by this paper
• Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer's disease.

  1996cited by this paper
• The synaptic protein NACP is abnormally expressed during the progression of Alzheimer's disease.

  1996cited by this paper
• Intraneuronal β-amyloid immunoreactivity in the CNS

  1996cited by this paper
• Impaired peripheral nerve regeneration in a mutant strain of mice (Enr) with a Schwann cell defect

  1995cited by this paper
• Antigen unmasking for immunoelectron microscopy: labeling is improved by treating with sodium ethoxide or sodium metaperiodate, then heating on retrieval medium.

  1995influential reference
• Induction of Alzheimer-like β-Amyloid Immunoreactivity in the Brains of Rabbits with Dietary Cholesterol

  1994cited by this paper
• Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease.

  1993cited by this paper

• The Role of Ceramide and Sphingosine-1-Phosphate in Alzheimer’s Disease and Other Neurodegenerative Disorders

  2019cites this paper
• Treatments and compositions targeting α-synuclein: a patent review (2010-2016)

  2017cites this paper
• Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice.

  2014cites this paper
• Alpha-Synuclein Transmission and Mitochondrial Toxicity in Primary Human Foetal Enteric Neurons In Vitro

  2013cites this paper
• Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model

  2013cites this paper
• Latrepirdine stimulates autophagy and reduces accumulation of α-synuclein in cells and in mouse brain

  2012cites this paper
• P4‐153: Increased Expression of the Lysosomal Cholesterol Transporter NPC1 in Alzheimer's Disease

  2010cites this paper
• Biochemical, cellular and behavioural aspects of neurodegeneration: The view from down under

  2009cites this paper
• Neurotoxins and neurotoxicity mechanisms. an overview

  2006cites this paper